Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1967 1
1969 1
1971 1
1973 1
1974 3
1975 1
1977 1
1978 8
1979 2
1982 2
1983 4
1984 5
1985 5
1986 1
1987 1
1988 7
1989 7
1990 8
1991 6
1992 4
1993 8
1994 5
1995 6
1996 11
1997 6
1998 10
1999 11
2000 14
2001 10
2002 26
2003 20
2004 13
2005 16
2006 21
2007 19
2008 27
2009 36
2010 37
2011 35
2012 55
2013 54
2014 39
2015 63
2016 57
2017 49
2018 52
2019 54
2020 44
2021 53
2022 39
2023 49
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

924 results

Results by year

Filters applied: . Clear all
Page 1
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Mendell JR, et al. Among authors: byrne bj. Mol Ther. 2021 Feb 3;29(2):464-488. doi: 10.1016/j.ymthe.2020.12.007. Epub 2020 Dec 10. Mol Ther. 2021. PMID: 33309881 Free PMC article. Review.
Dermato-oncology.
Hegazy S, Byrne B, Raulli G, Dhonncha EN. Hegazy S, et al. Among authors: byrne b. Clin Exp Dermatol. 2024 Mar 21;49(4):416-417. doi: 10.1093/ced/llad404. Clin Exp Dermatol. 2024. PMID: 38011611 No abstract available.
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, Toscano A, Castelli J, Díaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS; PROPEL Study Group. Schoser B, et al. Among authors: byrne bj. Lancet Neurol. 2021 Dec;20(12):1027-1037. doi: 10.1016/S1474-4422(21)00331-8. Lancet Neurol. 2021. PMID: 34800400 Clinical Trial.
Nicholas Muzyczka, PhD.
Berns KI, Byrne BJ, Flotte TR, Samulski RJ, Srivastava A. Berns KI, et al. Among authors: byrne bj. Mol Ther. 2023 Mar 1;31(3):607. doi: 10.1016/j.ymthe.2023.01.027. Epub 2023 Feb 10. Mol Ther. 2023. PMID: 36764298 Free PMC article. No abstract available.
Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.
Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, Nghiem PP, Ahn M, Meng H, Beatka MJ, Fickau BA, Prieto JC, Styner MA, Struharik MJ, Shanks C, Brown KJ, Golebiowski D, Bettis AK, Balog-Alvarez CJ, Clement N, Coleman KE, Corti M, Pan X, Hauschka SD, Gonzalez JP, Morris CA, Schneider JS, Duan D, Chamberlain JS, Byrne BJ, Kornegay JN. Birch SM, et al. Among authors: byrne bj. Sci Transl Med. 2023 Jan 4;15(677):eabo1815. doi: 10.1126/scitranslmed.abo1815. Epub 2023 Jan 4. Sci Transl Med. 2023. PMID: 36599002
924 results